Avacta Therapeutics has appointed Francis Wilson as its Chief Scientific Officer, recognizing his expertise in chemistry and contribution to the development of the pre|CISION® platform. Wilson’s background includes roles at Roche Discovery, Xenova, Cellzome, and Summit Therapeutics, where he led programs into clinical development. With a Ph.D. from Oxford University, Wilson brings a wealth of experience to Avacta. Former CSO Michelle Morrow will be leaving the company to pursue other opportunities. Avacta looks forward to leveraging Wilson’s leadership and expertise to advance their pre|CISION® platform and drug development efforts.

Read more at GlobeNewswire: Avacta appoints Francis Wilson as Chief Scientific Officer